Reforming 340B

04.16.14 | By

For the last 20 years, the federal 340B has helped biopharmaceutical companies and hospitals partner to share treatments and medicines at a discounted price with those who could not otherwise afford them. The program has helped millions of uninsured and vulnerable patients gain access to the treatments necessary to lead fuller — healthier lives. Unfortunately, the 340B program lacks an effective oversight mechanism to ensure the discounted treatments are reaching their intended recipients.

PhRMA 56th Annual Meeting Spotlights Conversion of Hope into Cures for Patients

04.16.14 | By

Last Friday marked another successful PhRMA Annual Meeting where the biopharmaceutical and patient community, policy makers, academics, and more, came together to discuss challenges and opportunities facing patients today. The Annual Meeting covered an array of topics all centering on the theme of: How we can convert hopes into cures for our nation’s patients.

Hepatitis C Debate Should Focus on Value of Innovative Medicines

04.15.14 | By

As the debate around the cost of Hepatitis C treatment rages on, a Bloomberg article yesterday highlighted other potential Hepatitis C medicines on the horizon and the many benefits they could provide for patients living with this debilitating disease. What’s more, many of the potential new medicines might be able to offer patients fewer unwanted side effects and require less monitoring and follow-up care.

#PhRMA14: Collaborating with Patients to Advance R&D

04.15.14 | By

Collaboration was rightly a focal point of #PhRMA14 because it is incredibly important to developing new medicines. As PhRMA CEO John Castellani said at the meeting, the industry is changing rapidly and we continue to compete by “joining hands…building new strength and breadth…[and] adapting and leading.” One of the most important ways to accomplish this is by incorporating the patient into everything we do. 

Stakeholders Urge Caution in Senate Consideration of Patent Reform

04.07.14 | By

ScientistBiopharmaceutical innovation is not a given.  Strong intellectual property protections are necessary to sustain America’s role as the worldwide leader in biopharmaceutical research and are critical to the biopharmaceutical industry’s ability to make the

Taking a Long-Term View on Cost of Care

03.31.14 | By

This month, a New York Times editorial discussed the cost of a new drug to treat hepatitis C. The opinion piece took a short-term view of treating the disease, noting that a panel of experts concluded that the drug offered “low value” for treating most patients, in large part due to its cost.

State, national leaders unite to fight diabetes in South Carolina

03.26.14 | By

South Carolina StatehouseThe magnificent architecture of the South Carolina State House served as the backdrop for Diabetes under the Dome – an event obviously focusing on one of the state’s worst health nightmares: diabetes.

Collaboration is What Will Help Drive New Successes for the Rare Disease Community

03.26.14 | By

While the number of patients with any individual rare disease is relatively small, they collectively affect 1 in 10 Americans. The community successfully comes together to raise awareness on international Rare Disease Day every February, but the challenge is how to maintain the momentum – and remain united - for the remaining 364 days of the year.

CMS’ Decision a Good Call for Patients

03.20.14 | By

In January, the Centers for Medicaid and Medicare Services (CMS) issued a proposed rule that would have adversely altered Medicare Part D’s six protected classes for prescription medication, restricting Medicare beneficiary access to antidepressants and immunosuppressants beginning in 2015.

Week in Review: Putting Patients First

03.14.14 | By

This week we focused on the role of patients within the R&D process, from discovery to market access. While the industry is continually striving to create new medicines, the more that patients, stakeholders, advocates and public and private sector leaders contribute feedback, ideas and ingenuity to the research and development (R&D) process, the better the likelihood of developing the next big breakthrough that will save or improve lives.

Pages

Subscribe to RSS - Opinion